Trefoil Therapeutics
About Trefoil Therapeutics
Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.
Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.
What does Trefoil Therapeutics do?
Trefoil Therapeutics is developing TTHX1114, an engineered Fibroblast Growth Factor (FGF1), for the treatment of corneal diseases affecting both the epithelial and endothelial layers of the cornea. The intracameral injection and topical formulations aim to improve visual recovery and reduce epithelial damage in patients with conditions such as Fuchs endothelial corneal dystrophy and other corneal injuries.
Where is Trefoil Therapeutics located?
Trefoil Therapeutics is based in San Diego, United States.
When was Trefoil Therapeutics founded?
Trefoil Therapeutics was founded in 2013.
How much funding has Trefoil Therapeutics raised?
Trefoil Therapeutics has raised $12.0M.
- Location
- San Diego, United States
- Founded
- 2013
- Funding
- $12.0M
- Employees
- 11 employees
- Investors
- Bios PartnersExsight VenturesSolasta Ventures
